Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 1;31(4):214-216.
doi: 10.1097/PRA.0000000000000863.

Contrave, Lybalvi, Auvelity, and Cobenfy: What Do They Have in Common?

Sheldon H Preskorn  1
Affiliations
Review

Contrave, Lybalvi, Auvelity, and Cobenfy: What Do They Have in Common?

Sheldon H Preskorn. J Psychiatr Pract. .

Abstract

This column reviews 4 psychiatric combination products: Contrave (bupropion + naltrexone), Lybalvi (olanzapine + samidorphan), Auvelity (dextromethorphan + bupropion), and Cobenfy (xanomeline + trospium). All have been approved in the last 11 years. These medications are all based on planned and therapeutic drug interactions involving pharmacokinetics and/or pharmacodynamics. In each case, the second drug in the combination enhances the efficacy and/or reduces the adverse effects of the first drug. This review illustrates how basic science in pharmacokinetics and brain circuitry was fundamental to the development of these products, particularly in the case of Contrave and Cobenfy.

Keywords: Auvelity; Cobenfy; Contrave; Lybalvi; combination products; drug-drug interactions; pharmacodynamics; pharmacokinetics; planned drug-drug interactions.

PubMed Disclaimer

References

    1. Contrave Prescribing Information. Nalpropion Pharmaceuticals; 2024. Accessed May 14, 2025. Available at: 200063s022lbl.pdf.
    1. Lybalvi Prescribing Information. Alkermes; 2025. Accessed May 14, 2025. Available at: 213378s008lbl.pdf.
    1. Auvelity Prescribing Information. Axsome Therapeutics; 2024. Accessed May 14, 2025. Available at: 215430s008lbl.pdf.
    1. Cobenfy Prescribing Information. Karuna Therapeutics, Inc., a Bristol-Myers Squibb company; 2024. Accessed May 14, 2024. Available at: 216158s000lbl.pdf.
    1. Preskorn S, Lacey R. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13:97–105.

MeSH terms

LinkOut - more resources